Lv31
248 积分 2021-04-04 加入
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
24分钟前
待确认
PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel
3个月前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
4个月前
已完结
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
4个月前
已完结
ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
4个月前
已关闭
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results
7个月前
已完结
Cancer statistics, 2022
8个月前
已完结
Advances in Radionuclide-Labeled Biological Carriers for Tumor Imaging and Treatment
8个月前
已完结
Integrative mapping of human CD8+ T cells in inflammation and cancer
9个月前
已完结
Categorization and Impact of Bridging Therapy Prior to CAR T-Cell Infusion in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
9个月前
已完结
皖公网安备34019202002308
